Effect of 0.2% brimonidine in preventing intraocular pressure elevation after Nd:YAG laser posterior capsulotomy

Ophthalmic Surgery and Lasers

Volumn 31, Issue 4, 2000, Pages 308-314

  Seong, Gong Je ^a,c   Lee, Young Ghee ^a   Lee, Jong Hyuk ^b   Lim, Seung Jeong ^a   Lee, Sung Chul ^a   Hong, Young Jae ^a   Kwon, Oh Woong ^a   Kim, Hong Bok ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University Wonju College of Medicine   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BRIMONIDINE;

ADULT; AGED; ARTICLE; CAPSULOTOMY; CLINICAL TRIAL; CONJUNCTIVA DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EYELID RETRACTION; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; NEODYMIUM LASER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC ALPHA-AGONISTS; CATARACT EXTRACTION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTRAOCULAR PRESSURE; INTRAOPERATIVE PERIOD; LASER SURGERY; LENS CAPSULE, CRYSTALLINE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; QUINOXALINES;

EID: 0343193109     PISSN: 10823069     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Brown SV, Thoma JV, Belcher CD, Simmons RJ. Effect of pilocarpine in treatment of intraocular pressure elevation following neodymium:YAG laser posterior capsulotomy. Ophthalmology. 1985; 92:354-359.
2. Richter CU, Arzeno G. Pappas HR, Steinert RF, Epstein DL. Intraocular pressure following Nd:YAG laser posterior capsulotomy. Ophthalmology. 1985;92:636-640.
3. Channell M, Beckman H. Intraocular pressure changes after neodymium-YAG laser posterior capsulotomy. Arch Ophthalmol. 1984;102:1024-1026.
4. Kraff MC, Sanders DR, Lieberman HL. Intraocular pressure and the corneal endothelium after neodymium-YAG laser posterior capsulotomy: relative effects of aphakia and pseudophakia. Arch Ophthalmol. 1985;103:511-514.
5. Stark WJ, Worthen D, Holladay JT, Murray G. Neodymium:YAG lasers: a FDA report. Ophthalmology. 1985;92:209-212.
6. Stilma JS, Boen-Tan TN. Timolol and intraocular pressure elevation following neodymium:YAG laser surgery. Doc Ophthalmol. 1986;61:233-239.
7. Terry AC, Stark WJ, Maumenee AK, Fagadau W. Neodymium-YAG laser for posterior capsulotomy. Am J Ophthalmol. 1983;96:716-720.
8. Flohr MJ, Robin AL, Kelley JS. Early complications following Q-switched neodymium:YAG laser posterior capsulotomy. Ophthalmology. 1985;92:360-363.
9. Barnebey HS, Robin AL, Zimmerman TJ, et al. The efficacy of brimonidine in decreasing elevations in intraocular pressure after laser trabeculoplasty. Ophthalmology. 1993;100:1083-88.
10. David R, Spaeth GL, Clevenger CE, et al. Brimonidine in the prevention of intraocular pressure elevation following argon laser trabeculoplasty. Arch Ophthalmol. 1993;111:1387-90.
11. Vine AK. Ocular hypertension following Nd:YAG laser capsulotomy: a potentially blinding complication. Ophthalmic Surg. 1984;15:283-284.
12. Toris CB, Gleason ML, Camras CB, et al. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol. 1995; 113:514-517.
13. Walters T. Development and use in treating acute chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies. Surv Ophthalmol. 1996:41(suppl):S19-26.
14. Silverstone DE, Novack GD, Kelley EP, Chen KS. Prophylactic treatment of intraocular pressure elevations after neodymium:YAG laser posterior capsulotomies and extracapsular cataract extractions with levobunolol. Ophthalmology. 1988;95:713-718.
15. Pollack IP, Brown RH, Crandall AS, Robin AL, Steinert RH, White GL. Prevention of the rise in intraocular pressure following neodymium-YAG posterior capsulotomy using topical 1% apraclonidine. Arch Ophthalmol. 1988;106:754-757.
16. Migliori ME, Beckman H, Channell MM. Intraocular pressure changes after neodymium-YAG laser capsulotomy in eyes pretreated with timolol. Arch Ophthalmol. 1987;105:473-475.
17. Richter CU, Arzeno G, Pappas HR, Arrigg CA, Wasson P, Steinert RF. Prevention of intraocular pressure elevation following neodymium-YAG laser posterior capsulotomy. Arch Ophthalmol. 1985;103:912-915.
18. Rakosfsky S, Koch DD, Faulkner JD, et al. Levobunolol 0.5% and timolol 0.5% to 18 prevent intraocular pressure elevation after neodymium:YAG laser posterior capsulotomy. J Cataract Refract Surg. 1997;23:1075-1080.
19. Chandler M, DeSantis L. Studies of apraclonidine as a potenitial antiglaucoma agent. Invest Ophthalmol Vis Sci. 1985:26(suppl):227.
20. Coleman A, Robin AL, Pollack I. Apraclonidine hydrochloride. In: Zimmerman TJ, Kooner KS, eds. Ophthalmol Clin N Am. Philadelphia, PA: WB Saunders Company; 1989:97-108.
21. Robin AL. Short-term effects of unilateral 1% apraclonidine therapy. Arch Ophthalmol. 1988;106:912-915.
22. Fahrenbach WH, Bacon DR, Van Buskirk EM. Microvascular responses to chronic glaucoma drug therapy. Invest Ophthalmol Vis Sci. 1991:32(suppl):944.
23. Fahrenbach WH, Bacon DR, Van Buskirk EM. Vasoactive drug effects on the uveal vasculature of the rabbit: a corrosion casting study. Invest Ophthalmol Vis Sci. 1989;30(suppl):100.
24. Van Buskirk EM, Bacon DR, Fahrenbach WH. Ciliary vasoconstriction after topical adrenergic drugs. Am J Ophthalmol. 1990;109:511-517.
25. Butler P, Mannschreck M, Lin S, Hwang I, Alvarado I. Clinical experience with the long-term use of 1% apraclonidine: incidence of allergic reactions. Arch Ophthalmol. 1995;113:293-296.
26. Robin AL. Questions concerning the role of apraclonidine in the management of glaucoma. Arch Ophthalmol. 1995;113:712-714.